Comparative Pharmacology
Head-to-head clinical analysis: LO OVRAL 28 versus LOARGYS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LO OVRAL 28 versus LOARGYS.
LO/OVRAL-28 vs LOARGYS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of norgestrel, a progestin, and ethinyl estradiol, an estrogen; suppresses gonadotropin secretion (FSH and LH) primarily via progestational activity, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial development, reducing implantation likelihood.
LOARGYS is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.
One tablet orally once daily for 28 days. Each tablet contains 0.3 mg norgestrel and 0.03 mg ethinyl estradiol. Active tablets (21 days) followed by placebo tablets (7 days).
100 mg orally twice daily.
None Documented
None Documented
Norgestrel: 20-40 hours; Ethinyl estradiol: 13-27 hours. Steady-state achieved after 3-5 half-lives.
Terminal elimination half-life: 12-18 hours (prolonged in renal impairment).
Renal (approx. 50% as metabolites, <1% unchanged); biliary/fecal (approx. 50% as metabolites).
Primarily renal (70-80% unchanged; 10-15% as metabolites); biliary/fecal (5-10%).
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive